Camilla Macapili Languille is the Head of Life Sciences within Mubadala’s Direct Investments platform where she oversees the firm’s private equity investments in pharmaceuticals, medtech, life science tools & diagnostics, healthcare IT, and provision, with a geographic focus on North America, Europe, and Asia.

Camilla joined Mubadala in 2013 and has over 20 years of experience working across multiple industries within the corporate finance and principal investment fields in North America, Europe and MENA, with a focus on healthcare, technology and industrials. Prior to Mubadala, Camilla worked in M&A and investments for Daiwa Capital and Société Générale based in Paris, and in investments for Virgin Group’s headquarters in London, where she managed the Special Situations portfolio and helped to launch Virgin Healthcare. She began her career in Healthcare M&A for JPMorgan in New York and London, focusing on pharma, medtech and biotech.

She currently serves on the Boards of PCI Pharma, Envirotainer, Evotec, Envision Pharma Group, and Citeline.

Camilla holds a Bachelor’s degree (summa cum laude) in Economics & Political Science from Columbia University. She has had an international upbringing and has lived in 14 countries across 4 continents. She is a Canadian national and is fluent in both English and French.